Lyra Therapeutics, INC 8-K filings

Lyra Therapeutics has entered into an agreement to terminate its sublease at 880 Winter Street, Waltham, for a $2.1 million payment.

Lyra Therapeutics has terminated its leases for facilities in Watertown and Waltham, Massachusetts, incurring significant termination fees and forfeiting security deposits.

Lyra Therapeutics, Inc. announced its common stock will be suspended from trading on Nasdaq following the withdrawal of its delisting appeal.

Lyra Therapeutics, Inc. received a notice of default for $484,431.92 in unpaid rent as it continues preparations for a wind-down of operations.

Lyra Therapeutics received a delisting notice from Nasdaq, citing its status as a public shell and non-compliance with stockholders' equity requirements, prompting an appeal.

Lyra Therapeutics announced the suspension of its lead product candidate LYR-210 development and a significant workforce reduction to preserve capital while exploring strategic alternatives.

Lyra Therapeutics announced Q3 2025 financial results and a plan for a new confirmatory Phase 3 clinical trial for LYR-210 for chronic rhinosinusitis without nasal polyps.

Lyra Therapeutics announced a clear regulatory path for its lead product candidate LYR-210 in chronic rhinosinusitis without nasal polyps following a successful Phase 3 trial and FDA discussions.

Lyra Therapeutics received a Nasdaq deficiency letter for failing to meet the minimum stockholders' equity requirement, risking potential delisting.

Lyra Therapeutics announced positive Phase 3 ENLIGHTEN 2 trial results for LYR-210 in chronic rhinosinusitis, extending its cash runway into Q3 2026 with new financing.

Lyra Therapeutics, Inc. announced the immediate termination of employment for Executive Chairman Harlan W. Waksal, M.D., with President and CEO Maria Palasis, Ph.D., simultaneously appointed as Chair of the Board.

Lyra Therapeutics, Inc. has announced a registered direct offering and concurrent private placement, raising approximately $5.0 million upfront, with potential for an additional $9.8 million from warrant exercises, following a recent Phase 3 clinical trial failure and significant employee terminations.

Lyra Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving a previous listing deficiency.

Lyra Therapeutics announced positive results from its ENLIGHTEN 2 Phase 3 trial for LYR-210 in chronic rhinosinusitis, outlining a strategic path forward for both non-polyp and polyp indications, contingent on securing additional financing.

Lyra Therapeutics announced positive results from its ENLIGHTEN 2 Phase 3 trial for LYR-210 in chronic rhinosinusitis, meeting primary and key secondary endpoints, alongside the implementation of a 1-for-50 reverse stock split.

Lyra Therapeutics' stockholders approved a reverse stock split at the Annual Meeting, with the board setting the ratio at 1-for-50, effective May 27, 2025.

Lyra Therapeutics reported its Q1 2025 financial results and is anticipating topline results from its ENLIGHTEN 2 Phase 3 trial of LYR210 in Chronic Rhinosinusitis (CRS) in Q2 2025.

Lyra Therapeutics announces its full year 2024 financial results and provides a corporate update, focusing on the upcoming ENLIGHTEN 2 Phase 3 trial results expected in Q2 2025.

Lyra Therapeutics is focusing on its ENLIGHTEN 2 Phase 3 trial for LYR-210 with data expected in Q2 2025, while planning a pivotal trial for polyp patients, contingent on securing additional financing.

Lyra Therapeutics reports the immediate resignation of two board members and the reclassification of another to balance board membership.

Lyra Therapeutics reported its Q3 2024 financial results and provided a corporate update, highlighting the upcoming ENLIGHTEN 2 Phase 3 trial results expected in Q2 2025.

Lyra Therapeutics reported its second quarter 2024 financial results and provided an update on its ENLIGHTEN Phase 3 clinical trials, highlighting positive subgroup data for LYR-210 in CRS patients with nasal polyps.

Lyra Therapeutics has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, putting its listing at risk.

Lyra Therapeutics' stockholders approved an amendment to the company's Restated Certificate of Incorporation to exculpate officers from certain breaches of fiduciary duty and elected two Class I directors at their annual meeting.

Lyra Therapeutics has amended its previous report to include an estimated $3.9 to $4.1 million in costs associated with a workforce reduction of up to 87 employees.

Lyra Therapeutics is reducing its workforce by up to 87 employees and providing retention payments to key executives as part of cost-reduction initiatives.

Lyra Therapeutics reported its Q1 2024 financial results and provided a corporate update, highlighting the upcoming Phase 3 trial results for LYR-210 in May.

Lyra Therapeutics reports the resignation of Edward T. Anderson from its Board of Directors and the appointment of Nancy L. Snyderman to the Audit Committee, both effective April 15, 2024.

Lyra Therapeutics reported its 2023 financial results and provided an update on its clinical programs, including the anticipated Q2 2024 topline results from the ENLIGHTEN I Phase 3 trial for LYR-210.

Lyra Therapeutics' Board of Directors has approved a 100% increase in the annual salary of Executive Chair, Harlan Waksal, M.D., effective retroactively to January 1, 2024.